-Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria

Press/Media

Period15 Apr 2019

Media coverage

1

Media coverage

  • Title-Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
    Media name/outletENP Newswire
    Date15/04/19
    PersonsManisha Balwani
View all 1
View less